Korro Bio Q3 2022 Earnings Report
Key Takeaways
Frequency Therapeutics reported its Q3 2022 financial results, including a cash position of $99.3 million. The company completed enrollment for the Phase 2b study of FX-322 and is on track for a Q4 clinical trial start of FX-345. A multiple sclerosis remyelination program candidate was advanced to IND-enabling studies.
Enrollment completed for Phase 2b study of FX-322, with readout expected in Q1 2023.
Company on track for Q4 clinical trial start of its second hearing restoration program, FX-345.
Multiple Sclerosis Remyelination Program Candidate Advanced to IND-Enabling Studies, with Anticipated 2H 2023 IND Filing.
Cash, cash equivalents and marketable securities as of September 30, 2022, were $99.3 million.
Korro Bio
Korro Bio
Forward Guidance
Frequency Therapeutics believes its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations into 2024.